The new epidemic of Coruna opened the war between the epidemiologist Didier Rawl, head of the Infectious Diseases Department at the Hospital of Marcellia Didier Rawlett, who adheres to the drug “chloroquine” as a treatment for the emerging coronavirus, and the head of the infectious diseases department at Saint Antoine Hospital in Paris Karen Lacombe who launched a war against him and defends treatment with ” Blood plasma ». But Raul offers a cheap and inexpensive drug and the second suggests a prescription for salivating multinational laboratories.
The use of hydroxychloroquine to treat the emerging coronavirus has sparked controversy among scientists and politicians.
There were indications that the drug was effective in treatment, but the tests did not carry due care of extensive clinical trials.
However, many, including US President Donald Trump, are calling on doctors to prescribe hydroxychloroquine to patients.
A report of the British newspaper “Daily Mail” revealed a poll in which 6,200 doctors from 30 countries confirmed that the malaria drug hydroxychloroquine was more effective in treating people with coronavirus, as doctors throughout Europe, the United States, Africa, and China were granted a license to prescribe this drug to Corona patients. Although the World Health Organization has confirmed that there is no drug that can prevent or cure the virus so far.
Last Thursday, French President Emmanuel Macron met Didier Raoul, owner of clinical trials and research urging the use of chloroquine to treat corona.
This visit is the beginning of France’s official recognition of the efforts of this doctor, who raised a lot of controversy at the beginning, but public opinion and international and French health authorities no longer exclude the hypothesis of the success of the vaccine he proposes.
On the other hand, last Tuesday, the health authorities in France, led by the head of the Infectious Diseases Department at Saint-Antoine Hospital in Paris, Karen Lacombe, began the first clinical trials in an attempt to find a vaccine for a pandemic in various parts of the world, with the subject of 60 patients with the virus, to conduct a trial «transfer of plasma recoverers, from “Previous patients have overcome the disease.”
The clinical experience is based on raising the immunity of patients through the plasma of the patients, so that their bodies can withstand the virus, and a preliminary evaluation can be made two to 3 weeks after the start of the clinical trial, which can be extended depending on the results.
The development of this immunoglobulin will need to collect plasma from donors who have fully recovered from Covid-19 disease, and whose blood contains antibodies that are able to fight the emerging corona virus. After collection, the “recovery” plasma will be transferred to manufacturing facilities where it will undergo a special treatment process, including effective processes to disable and eliminate the virus, and then be incorporated in its pure form into the product.
The efficacy of plasma has been demonstrated in those recovering, a part of the liquid blood in which antibodies are concentrated after a disease, in small-scale studies against other infectious diseases such as “Ebola” and “SARS”. And the US Food and Drug Administration has given approval to conduct experiments on such potential treatments against the emerging corona virus.